| Unique ID issued by UMIN | UMIN000063181 |
|---|---|
| Receipt number | R000072309 |
| Scientific Title | A nationwide cohort study on long-term outcomes of hemodiafiltration in incident dialysis patients: dose-response relationship of substitution volume |
| Date of disclosure of the study information | 2026/10/05 |
| Last modified on | 2026/10/05 19:43:37 |
A nationwide cohort study on long-term outcomes of hemodiafiltration in incident dialysis patients: dose-response relationship of substitution volume
HDF volume and outcomes in incident dialysis
A nationwide cohort study on long-term outcomes of hemodiafiltration in incident dialysis patients: dose-response relationship of substitution volume
HDF dose-response in incident dialysis
| Japan |
End-stage kidney disease requiring dialysis initiation
| Nephrology |
Others
NO
To examine whether hemodiafiltration (HDF), compared with hemodialysis (HD), reduces all-cause mortality in incident dialysis patients, and whether a dose-response relationship exists between HDF substitution volume (<40 L / 40-49 L / 50 L or more) and all-cause mortality.
Efficacy
Confirmatory
Not applicable
All-cause mortality during follow-up from the exposure assessment time
1) Cardiovascular mortality and infection-related mortality (cause-specific Cox models)
2) Dose-response relationship between HDF substitution volume and all-cause mortality (restricted cubic splines)
3) Risk differences and restricted mean survival time (RMST) differences at 3, 5 and 8 years
Observational
| 18 | years-old | <= |
| Not applicable |
Male and Female
Patients who initiated maintenance dialysis between January 2015 and September 2023 at facilities participating in the JSDT Renal Data Registry (JRDR)
Age <18 years; history of PD or kidney transplantation before HD/HDF initiation; death, transplantation or loss to follow-up before the exposure assessment time; not thrice-weekly dialysis; session <4 h; blood flow <180 mL/min; excluded modalities (offline/push-pull HDF, AFBF, IHDF, home HD, etc.); combined HD/HDF or PD therapy
380000
| 1st name | Tomoyuki |
| Middle name | |
| Last name | Fujikura |
Hamamatsu University School of Medicine
Internal Medicine 1
431-3192
1-20-1 Handayama, Chuo-ku, Hamamatsu city, Shizuoka
053-435-2261
tfuji@hama-med.ac.jp
| 1st name | Tomoyuki |
| Middle name | |
| Last name | Fujikura |
Hamamatsu University School of Medicine
Internal Medicine 1
431-3192
1-20-1 Handayama, Chuo-ku, Hamamatsu city, Shizuoka
053-435-2261
tfuji@hama-med.ac.jp
Hamamatsu University School of Medicine
Self funding
Self funding
Japan
Ethics Committee, Japanese Society for Dialysis Therapy
2-38-21 Hongo, Bunkyo-ku, Tokyo
03-5800-0708
office@jsdt.or.jp
YES
26-2
Medicine Ethics Committee of the Japanese Society for Dialysis Therapy
浜松医科大学(静岡県)
| 2026 | Year | 10 | Month | 05 | Day |
Unpublished
380000
No longer recruiting
| 2026 | Year | 08 | Month | 20 | Day |
| 2026 | Year | 08 | Month | 20 | Day |
| 2026 | Year | 08 | Month | 20 | Day |
| 2026 | Year | 12 | Month | 31 | Day |
A retrospective cohort study (as-treated analysis) using secondary data from the Japanese Society for Dialysis Therapy Renal Data Registry (JRDR). Incident dialysis patients (January 2015 to September 2023) are classified into HD and HDF groups (substitution volume <40 L / 40-49 L / 50 L or more). Follow-up is up to approximately 9 years (administrative censoring at the end of 2024). All-cause mortality is analyzed by IPTW-weighted Cox models, with dose-response assessed using restricted cubic splines.
| 2026 | Year | 10 | Month | 05 | Day |
| 2026 | Year | 10 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072309